2020
The Role of Bile Acid‐Mediated Inflammation in Cholestatic Liver Injury
Cai S, Li M, Boyer J. The Role of Bile Acid‐Mediated Inflammation in Cholestatic Liver Injury. 2020, 728-736. DOI: 10.1002/9781119436812.ch56.Peer-Reviewed Original ResearchCholestatic liver injuryBile acidsLiver injuryProinflammatory mediatorsInflammatory responseCauses of cholestasisAlcoholic liver diseasePrimary biliary cholangitisConjugated bile acidsEffects of drugsHepatic infiltrationBile acid transporterLiver transplantationViral hepatitisBiliary cholangitisBiliary cirrhosisMetabolic syndromeDuct obstructionLiver diseaseImmune cellsNeutrophil activationPathophysiological levelsCholangitisInflammationInjury
2015
Fibrates and cholestasis
Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology 2015, 62: 635-643. PMID: 25678132, PMCID: PMC4515188, DOI: 10.1002/hep.27744.BooksConceptsPrimary sclerosing cholangitisPrimary biliary cirrhosisCholestatic liver diseaseUDCA therapyLiver diseaseUrsodeoxycholic acidNuclear receptorsProgression of PBCHepatic transportersPeroxisome proliferator-activated receptor alphaProliferator-activated receptor alphaToxic bile constituentsApical sodium-dependent bile salt transporterOnly therapeutic optionCholestatic liver disordersBile acid homeostasisBile acid synthesisBile salt transportersMultidrug resistance protein 3Cytochrome P450PPARα effectLiver transplantationSclerosing cholangitisBiliary cirrhosisLiver failure
2013
The role of macrophage migration inhibitory factor in autoimmune liver disease
Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, Mizue Y, Nikolic‐Paterson D, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, Bucala R. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology 2013, 59: 580-591. PMID: 23913513, PMCID: PMC3877200, DOI: 10.1002/hep.26664.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, Differentiation, B-LymphocyteBiomarkersBiopsyCase-Control StudiesCohort StudiesFemaleGene FrequencyHepatitis, AutoimmuneHistocompatibility Antigens Class IIHumansIntramolecular OxidoreductasesLiverLiver Cirrhosis, BiliaryMacrophage Migration-Inhibitory FactorsMaleMicrosatellite RepeatsMiddle AgedPhenotypePolymorphism, Single NucleotideConceptsMacrophage migration inhibitory factorPrimary biliary cirrhosisAutoimmune hepatitisMigration inhibitory factorMIF receptorHealthy controlsInhibitory factorAutoimmune liver diseaseMIF promoter polymorphismsHepatic stellate cellsEnzyme-linked immunosorbentCATT7 alleleImmunopathogenic basisMIF expressionMIF locusBiliary cirrhosisLiver diseaseInflammatory phenotypeReceptor profileStellate cellsPromoter polymorphismPatientsSerum samplesCD74Single nucleotide polymorphisms
2001
Cholestatic syndromes
Trauner M, Boyer J. Cholestatic syndromes. Current Opinion In Gastroenterology 2001, 17: 242-256. PMID: 17031165, DOI: 10.1097/00001574-200105000-00007.Peer-Reviewed Original ResearchCholestatic syndromeTotal parenteral nutrition-induced cholestasisParenteral nutrition-induced cholestasisHereditary cholestatic syndromesPrimary biliary cirrhosisCholestasis of pregnancyCholestatic liver diseaseDrug-induced cholestasisHepatobiliary transport proteinsBiliary cirrhosisClinical featuresLiver diseaseBile secretionCholestasisSyndromePathogenesisImportant new studiesNew studiesCholangitisCirrhosisPregnancyDiseaseSecretionTransporter gene
2000
Cholestatic syndromes
Trauner M, Boyer J. Cholestatic syndromes. Current Opinion In Gastroenterology 2000, 16: 239-250. PMID: 17023881, DOI: 10.1097/00001574-200005000-00006.Peer-Reviewed Original Research
1999
The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis
Combes B, Markin R, Wheeler D, Rubin R, West A, Mills A, Eigenbrodt E, Maddrey W, Munoz S, Garcia‐Tsao G, Bonner G, Boyer J, Luketic V, Shiffman M, Peters M, White H, Zetterman R, Carithers R. The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. Hepatology 1999, 30: 602-605. PMID: 10462363, PMCID: PMC3935822, DOI: 10.1002/hep.510300315.Peer-Reviewed Original ResearchConceptsFlorid duct lesionsPrimary biliary cirrhosisBile duct destructionDuct lesionsUrsodeoxycholic acidDuct destructionBiliary cirrhosisPlacebo-controlled trialNeedle biopsy specimensUDCA patientsAdvanced diseasePlacebo medicationEarly diseaseBiopsy specimensPatientsLesionsBeneficial effectsPathology literaturePrevalenceCirrhosisPlaceboMedicationsDiseaseYearsHepatopathologistBiliary bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid
Combes B, Carithers R, Maddrey W, Munoz S, Garcia‐Tsao G, Bonner G, Boyer J, Luketic V, Shiffman M, Peters M, White H, Zetterman R, Risser R, Rossi S, Hofmann A. Biliary bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid. Hepatology 1999, 29: 1649-1654. PMID: 10347103, PMCID: PMC4004074, DOI: 10.1002/hep.510290618.Peer-Reviewed Original ResearchMeSH KeywordsBileBile Acids and SaltsChenodeoxycholic AcidCholic AcidChromatography, GasChromatography, High Pressure LiquidDeoxycholic AcidDouble-Blind MethodDrug Administration ScheduleFemaleHumansLithocholic AcidLiver Cirrhosis, BiliaryMaleMiddle AgedPlacebosRegression AnalysisReproducibility of ResultsTime FactorsUrsodeoxycholic AcidConceptsPrimary biliary cirrhosisBile acid compositionUrsodeoxycholic acidBile acidsBiliary cirrhosisSeverity of PBCSingle bedtime dosePlacebo-controlled trialBiliary bile acidsEndogenous bile acidsMajor bile acidsBedtime dosePlacebo medicationDuodenal bileHigh-pressure liquid chromatography methodPatientsNormal personsBileSignificant decreaseCirrhosisAcid compositionCDCATaurineLiquid chromatography methodYearsCholestatic syndromes
Trauner M, Boyer J. Cholestatic syndromes. Current Opinion In Gastroenterology 1999, 15: 217-228. PMID: 17023948, DOI: 10.1097/00001574-199905000-00006.Peer-Reviewed Original ResearchCholestatic syndromeBile duct lossPathogenesis of pruritusCholestatic liver injuryPrimary biliary cirrhosisCholestasis of pregnancyCholestatic liver diseaseDrug-induced cholestasisNew treatment strategiesHepatobiliary transport systemsBiliary cirrhosisLiver injuryClinical featuresLiver diseaseTreatment strategiesDuct lossCholestasisSyndromePathogenesisImportant new studiesNew studiesImportant mechanismCholangitisCirrhosisPruritus
1995
A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
Combes B, Carithers R, Maddrey W, Lin D, Mcdonald M, Wheeler D, Eigenbrodt E, Muñoz S, Rubin R, Garcia-tsao G, Bonner G, West A, Boyer J, Luketic V, Shiffman M, Mills A, Peters M, White H, Zetterman R, Rossi S, Hofmann A, Markin R. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22: 759-766. DOI: 10.1016/0270-9139(95)90294-5.Peer-Reviewed Original ResearchPrimary biliary cirrhosisSerum bilirubinBiliary cirrhosisMajor complicationsStratum 1Liver diseaseTreatment failureAdvanced primary biliary cirrhosisPlacebo-treated patientsPlacebo-controlled trialBile acid poolStratum 3Advanced diseaseLiver histologyPrognostic factorsMilder diseaseSingle doseUrsodeoxycholic acidUrsodiolSevere symptomsPatientsPlaceboLaboratory testsComplicationsBilirubinA randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
Combes B, Carithers R, Maddrey W, Lin D, McDonald M, Wheeler D, Eigenbrodt E, Muñoz S, Rubin R, Garcia‐Tsao G, Bonner G, West A, Boyer J, Luketic V, Shiffman M, Mills A, Peters M, White H, Zetterman R, Rossi S, Hofmann A, Markin R. A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22: 759-766. PMID: 7657280, DOI: 10.1002/hep.1840220311.Peer-Reviewed Original ResearchConceptsPrimary biliary cirrhosisSerum bilirubinBiliary cirrhosisStratum 1Advanced primary biliary cirrhosisPlacebo-controlled trialBile acid poolLiver histologyPrognostic factorsTreatment failureSingle doseUrsodeoxycholic acidSevere symptomsPatientsUrsodiolLaboratory testsPlaceboHistologyBilirubinCirrhosisBiochemical testsGood responseStratum 3Acid poolLess effect
1994
Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years
Mahl T, Shockcor W, Boyer J. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. Journal Of Hepatology 1994, 20: 707-713. PMID: 7930469, DOI: 10.1016/s0168-8278(05)80139-4.Peer-Reviewed Original ResearchConceptsTime of diagnosisAsymptomatic patientsSurvival of patientsGender-matched control populationPrimary biliary cirrhosisMedian followElevated bilirubinOverall survivalSymptomatic patientsAdvanced fibrosisBile stasisBiliary cirrhosisIndependent predictorsLiver biopsyLiver diseaseDiminished survivalLarge cohortPatientsOriginal diagnosisAccurate followControl populationSymptomsSurvival dataDiagnosisSurvival
1985
Asymptomatic primary biliary cirrhosis A progress report on long-term follow-up and natural history
Beswick D, Klatskin G, Boyer J. Asymptomatic primary biliary cirrhosis A progress report on long-term follow-up and natural history. Gastroenterology 1985, 89: 267-271. PMID: 4007417, DOI: 10.1016/0016-5085(85)90325-7.Peer-Reviewed Original ResearchConceptsAsymptomatic primary biliary cirrhosisPrimary biliary cirrhosisBiliary cirrhosisAsymptomatic stateGeneral populationInitial liver biopsySubgroup of patientsLife table survival analysisDevelopment of symptomsMedian followPortal granulomasOverall survivalProgressive diseaseLiver biopsyLiver diseaseMedian periodAutoimmune disordersExtended followHistologic featuresBenign outcomeCirrhosisPatientsSurvival analysisNatural historySymptoms
1983
The Prognostic Importance of Clinical and Histologic Features in Asymptomatic and Symptomatic Primary Biliary Cirrhosis
Roll J, Boyer J, Barry D, Klatskin G. The Prognostic Importance of Clinical and Histologic Features in Asymptomatic and Symptomatic Primary Biliary Cirrhosis. New England Journal Of Medicine 1983, 308: 1-7. PMID: 6847917, DOI: 10.1056/nejm198301063080101.Peer-Reviewed Original ResearchConceptsPrimary biliary cirrhosisBiliary cirrhosisPoor prognosisSymptomatic primary biliary cirrhosisOnset of diseaseAsymptomatic patientsAsymptomatic diseaseClinical featuresHistologic featuresHistologic stagePrediction of riskPrognostic importanceSerum bilirubinHepatic fibrosisHistologic findingsPortal areasProlonged survivalMultivariate analysisPatientsControl populationPrognosisWeight lossElevated levelsLife expectancySurvival data
1980
Bone disease in primary biliary cirrhosis: Reversal of osteomalacia with oral 25-hydroxyvitamin D
Reed J, Meredith S, Nemchausky B, Rosenberg I, Boyer J. Bone disease in primary biliary cirrhosis: Reversal of osteomalacia with oral 25-hydroxyvitamin D. Gastroenterology 1980, 78: 512-517. PMID: 7351289, DOI: 10.1016/0016-5085(80)90865-3.Peer-Reviewed Original ResearchConceptsPrimary biliary cirrhosisBiliary cirrhosisBone biopsyBone diseaseIliac crest bone biopsiesMineralized bone massVitamin D deficiencyRelative osteoid volumeCrest bone biopsiesTrabecular bone volumeLow serum concentrationsD deficiencyD therapySerum concentrationsOsteoid volumeBone massTreatment periodOsteoid surfaceBone volumeOsteomalaciaHistomorphometric analysisCirrhosisPatientsBone mineralizationBiopsy
1979
Phenobarbital treatment in primary biliary cirrhosis. Differences in bile acid composition between responders and nonresponders.
Stellaard F, Bolt M, Boyer J, Klein P. Phenobarbital treatment in primary biliary cirrhosis. Differences in bile acid composition between responders and nonresponders. Translational Research 1979, 94: 853-61. PMID: 501209.Peer-Reviewed Original Research